1
|
Zhang S, Huang L, Zeng Y, Gao G, Wu H, Li D, Guo R. SLC38A3 Promotes the Proliferation and Migration of Tumor Cells and Predicts Poor Prognosis in Colorectal Cancer. ACS OMEGA 2024; 9:21116-21126. [PMID: 38764627 PMCID: PMC11097367 DOI: 10.1021/acsomega.4c00901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/28/2024] [Revised: 04/05/2024] [Accepted: 04/24/2024] [Indexed: 05/21/2024]
Abstract
Previous studies have revealed that abnormal expressions of membrane transporters were associated with colorectal cancer (CRC). We herein performed a comprehensive bioinformatics analysis to identify the key transporter protein-related genes involved in CRC and potential mechanisms. Differentially expressed transporter protein-related genes (DE-TPRGs) were identified from CRC and normal samples using The Cancer Genome Atlas database. SLC38A3 expression was validated by immunohistochemistry and RT-qPCR, and the potential mechanism was explored. A total of 63 DE-TPRGs (29 up-regulated and 34 down-regulated) were screened. Inside, ABCC2, ABCG2, SLC4A4, SLC9A3, SLC15A1, and SLC38A3 were identified as hub genes. SLC38A3 is indeed upregulated in colorectal cancer patients. Furthermore, we found that knockdown of SLC38A3 inhibited the proliferation and migration of HCT116 cells, and Hsp70 ATPase activator could rescue it. Overall, SLC38A3 is a novel potential biomarker involved in CRC progression and promotes the proliferation and migration of tumor cells by positively regulating the function of Hsp70.
Collapse
Affiliation(s)
- Siyi Zhang
- Department
of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Lingli Huang
- Department
of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Youjie Zeng
- Department
of Anesthesiology, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Ge Gao
- Department
of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Hui Wu
- Department
of Laboratory Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Dai Li
- Phase
I Clinical Tria Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China
- National
Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan 410005, China
| | - Ren Guo
- Department
of Pharmacy, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| |
Collapse
|
2
|
Papavassiliou AG, Delle Cave D. Novel Therapeutic Approaches for Colorectal Cancer Treatment. Int J Mol Sci 2024; 25:2228. [PMID: 38396903 PMCID: PMC10889277 DOI: 10.3390/ijms25042228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2024] [Accepted: 02/07/2024] [Indexed: 02/25/2024] Open
Abstract
According to GLOBOCAN 2020 data, colorectal cancer (CRC) represents the third most common malignancy and the second most deadly cancer worldwide [...].
Collapse
Affiliation(s)
- Athanasios G. Papavassiliou
- Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece;
| | - Donatella Delle Cave
- Institute of Genetics and Biophysics ‘Adriano Buzzati-Traverso’, CNR, 80131 Naples, Italy
| |
Collapse
|
3
|
Tobi M, Antaki F, Rambus MA, Yang YX, Kaplan D, Rodriguez R, Maliakkal B, Majumdar A, Demian E, Tobi YY, Sochacki P, Ehrinpreis M, Lawson MG, McVicker B. The Non-Invasive Prediction of Colorectal Neoplasia (NIPCON) Study 1995-2022: A Comparison of Guaiac-Based Fecal Occult Blood Test (FOBT) and an Anti-Adenoma Antibody, Adnab-9. Int J Mol Sci 2023; 24:17257. [PMID: 38139086 PMCID: PMC10743815 DOI: 10.3390/ijms242417257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/27/2023] [Accepted: 12/06/2023] [Indexed: 12/24/2023] Open
Abstract
Given the need to improve the sensitivity of non-invasive methods to detect colorectal neoplasia, particularly adenomas, we compared a fecal test using a monoclonal antibody (Mab) raised against constituents of colonic adenomas designated Adnab-9 (Adenoma Antibody 9), recognizing an N-linked 87 kDa glycoprotein, to gFOBT, which is shown to reduce CRC mortality. p87 immunohistochemistry testing is significantly more sensitive (OR 3.64[CI 2.37-5.58]) than gFOBT (guaiac-based fecal occult blood test) for adenomas (<3 in number), advanced adenomas (OR 4.21[CI 2.47-7.15]), or a combination of the two (OR 3.35[CI 2.47-4.53]). p87 immunohistochemistry shows regional Paneth cell (PC) expression mainly in the right-sided colon and is significantly reduced in the ceca of African Americans (p < 0.0001). In a subset of patients, we obtained other body fluids such as urine, colonic effluent, and saliva. Urine tests (organ-specific neoantigen) showed a significant difference for advanced adenomas (p < 0.047). We conclude that fecal p87 testing is more sensitive than gFOBT and Adnab-9 and could be used to better direct the colonoscopy screening effort.
Collapse
Affiliation(s)
- Martin Tobi
- Department of Research and Development, John D. Dingell VAMC, Detroit, MI 48201, USA; (F.A.)
| | - Fadi Antaki
- Department of Research and Development, John D. Dingell VAMC, Detroit, MI 48201, USA; (F.A.)
| | - Mary Ann Rambus
- Department of Research and Development, John D. Dingell VAMC, Detroit, MI 48201, USA; (F.A.)
| | - Yu-Xiao Yang
- Department of Research and Development, Philadelphia VAMC, Philadelphia, PA 19104, USA (D.K.); (R.R.)
| | - David Kaplan
- Department of Research and Development, Philadelphia VAMC, Philadelphia, PA 19104, USA (D.K.); (R.R.)
| | - Rebecca Rodriguez
- Department of Research and Development, Philadelphia VAMC, Philadelphia, PA 19104, USA (D.K.); (R.R.)
| | | | - Adhip Majumdar
- Department of Research and Development, John D. Dingell VAMC, Detroit, MI 48201, USA; (F.A.)
| | - Ereny Demian
- Departments of Medicine, State University of Pennsylvania, State College, PA 16802, USA;
| | - Yosef Y. Tobi
- New York Medical College, Touro University, Valhalla, NY 10595, USA
| | - Paula Sochacki
- Department of Research and Development, John D. Dingell VAMC, Detroit, MI 48201, USA; (F.A.)
| | - Murray Ehrinpreis
- Detroit Medical Center, Wayne State University School of Medicine, Detroit, MI 48201, USA
| | | | | |
Collapse
|